Generation of an Alagille syndrome (ALGS) patient-derived induced pluripotent stem cell line (TRNDi032-A) carrying a heterozygous mutation (p.Cys682Leufs*7) in the JAG1 gene

Omer Hatim, Ivan Pavlinov, Miao Xu, Kaari L. Linask, Jeanette Beers, Chengyu Liu, Karsten Baumgärtel, Melissa A. Gilbert, Nancy B. Spinner, Catherine Chen, Jizhong Zou, Wei ZhengStem 2023 · DOI

TL;DR

This paper reports the successful generation and characterization of a new induced pluripotent stem cell (iPSC) line, TRNDi032-A, derived from a patient with Alagille syndrome (ALGS). This iPSC line carries a specific genetic mutation in the JAG1 gene, offering a valuable tool for understanding ALGS pathogenesis and developing new therapeutic strategies.

What Problem Does This Paper Address?

Alagille syndrome (ALGS) is a complex, autosomal dominant genetic disorder that affects multiple organ systems, primarily the liver, heart, and skeleton. It's caused by mutations in either the JAG1 or NOTCH2 genes, which are crucial for the Notch signaling pathway. The disease presents with significant variability in its symptoms and severity, making diagnosis and treatment challenging. Currently, there are no cures for ALGS, and existing treatments are often invasive or focus on symptom management. The lack of robust cell-based models that accurately recapitulate the disease's genetic basis hinders research into its underlying mechanisms and the development of effective therapies. This paper addresses this gap by creating a patient-derived iPSC line that carries a specific, disease-causing mutation in the JAG1 gene.

Methods

The researchers employed standard, yet rigorous, techniques for generating and characterizing human induced pluripotent stem cells (iPSCs).

  • Episomal Reprogramming: Peripheral blood cells from an ALGS patient were reprogrammed into iPSCs using episomal vectors. This method introduces specific transcription factors (OCT4, KLF4, SOX2, and C-MYC) to revert somatic cells to a pluripotent state without integrating into the host genome.
  • Cell Culture and Expansion: The generated iPSC colonies were cultured and expanded using specialized media (TeSR-E7, E8, and StemFlex) on Matrigel-coated plates.
  • Genetic Validation:
    • Whole Genome Sequencing (WGS): Used to confirm the presence of the specific heterozygous mutation (p.Cys682Leufs*7, c.2044dup) in the JAG1 gene.
  • Sanger Sequencing: Performed to further validate the identified mutation.
  • G-banded Karyotyping: Assessed for chromosomal abnormalities, ensuring the iPSC line had a normal karyotype (46, XY).
  • Short Tandem Repeat (STR) DNA Profiling: Verified the identity and genetic lineage of the iPSC line by comparing it to the parental cell line.
  • Pluripotency and Differentiation Assays:
    • Immunocytochemistry: Confirmed the expression of key pluripotency markers (OCT4, SOX2, SSEA4, TRA-1-60, NANOG) using immunofluorescence.
  • Flow Cytometry: Quantified the co-expression of pluripotency markers (TRA-1-81 and SSEA-4).
  • Teratoma Formation Assay: Evaluated the in vivo differentiation potential of the iPSC line into the three germ layers (ectoderm, mesoderm, and endoderm) by injecting them into immunocompromised mice.
  • Quality Control:
    • Mycoplasma Detection: Ensured the cell line was free from mycoplasma contamination.

Datasets

  • Patient-Derived Lymphoblasts: The primary source material for generating the iPSC line was peripheral blood cells (lymphoblasts) from a 9-month-old male patient with Alagille syndrome.
  • Parental Cell Line (AGS591P): STR DNA profiling was used to match the generated iPSC line to its parental cell line.

Key Insights and Ideas

  • A Patient-Specific ALGS Model: The creation of TRNDi032-A provides a crucial, patient-specific model for studying Alagille syndrome. This allows researchers to investigate the disease's mechanisms in a human cellular context, which is more relevant than animal models alone.
  • Targeted Therapeutic Development: The iPSC line carries a well-defined heterozygous mutation in JAG1, enabling the study of how this specific genetic defect impacts cellular function. This is vital for developing targeted therapies that can correct or compensate for the gene's haploinsufficiency.
  • Potential for In Vitro Disease Modeling: The ability to differentiate these iPSCs into various cell types, such as hepatocytes, opens doors for in vitro disease modeling. This could allow for the screening of potential drug candidates and the assessment of their efficacy and toxicity in a controlled environment.
  • Comprehensive Characterization: The paper details a thorough characterization of the iPSC line, including genetic, phenotypic, and functional assessments. This ensures the reliability and utility of the cell line for future research.

Key Results

  • Successful iPSC Generation: A stable human iPSC line (TRNDi032-A) was successfully generated from an ALGS patient's lymphoblasts.
  • Confirmed Genetic Mutation: The iPSC line was confirmed to carry the heterozygous mutation p.Cys682Leufs*7 (c.2044dup) in the JAG1 gene, consistent with ALGS type 1.
  • Pluripotency Confirmed: The iPSC line expressed standard pluripotency markers (OCT4, SOX2, SSEA4, TRA-1-60, NANOG) and demonstrated normal morphology. Flow cytometry showed high co-expression of TRA-1-81 and SSEA-4 (92.03%).
  • Normal Karyotype: G-banded karyotype analysis revealed a normal chromosomal complement (46, XY).
  • In Vivo Differentiation Potential: The teratoma formation assay confirmed the iPSC line's ability to differentiate into all three germ layers (ectoderm, mesoderm, and endoderm).
  • Mycoplasma-Free: The cell line tested negative for mycoplasma contamination.
  • Identity Verified: STR DNA profiling confirmed the iPSC line's identity matched its parental cell line.

Limitations and Future Work

  • Limited Scope of Mutation: While this iPSC line carries a specific JAG1 mutation, ALGS can also be caused by NOTCH2 mutations or other JAG1 mutations. Therefore, this model is specific to the characterized mutation.
  • In Vitro vs. In Vivo Complexity: While the iPSC line can be differentiated into various cell types, fully recapitulating the complex multisystemic nature of ALGS in vitro remains a challenge.
  • Future Work: The authors suggest that this iPSC line can be used to derive hepatocytes for in vitro assays to further elucidate ALGS pathogenesis and to develop novel therapeutics for patient treatment. Further studies could involve differentiating these iPSCs into other relevant cell types (e.g., cardiac or vascular cells) to model other aspects of the disease.

Summary updated

Abstract

Alagille syndrome (ALGS) is an autosomal dominant, multisystemic disorder due to haploinsufficiency in either the JAG1 gene (ALGS type 1) or the NOTCH2 gene (ALGS type 2). The disease has been difficult to diagnose and treat due to its muti-system clinical presentation, variable expressivity, and prenatal onset for some of the features. The generation of this iPSC line (TRNDi032-A) carrying a heterozygous mutation, p.Cys682Leufs*7 (c.2044dup), in the JAG1 gene provides a means of studying the disease and developing novel therapeutics towards patient treatment.
BibTeX
@inproceedings{hatim2023generation,
  author = {Omer Hatim and Ivan Pavlinov and Miao Xu and Kaari L. Linask and Jeanette Beers and Chengyu Liu and Karsten Baumgärtel and Melissa A. Gilbert and Nancy B. Spinner and Catherine Chen and Jizhong Zou and Wei Zheng},
  title = {{Generation of an Alagille syndrome (ALGS) patient-derived induced pluripotent stem cell line (TRNDi032-A) carrying a heterozygous mutation (p.Cys682Leufs*7) in the JAG1 gene}},
  booktitle = {Stem},
  year = {2023},
  doi = {10.1016/j.scr.2023.103231},
}
Figure